Anti-Inflammatory Effects and Molecular Mechanisms of Shenmai Injection in Treating Acute Pancreatitis: Network Pharmacology Analysis and Experimental Verification
DOI: https://doi.org/10.2147/DDDT.S364352
2022-08-03
Abstract:Yanqiu He, 1, &ast Cheng Hu, 1, &ast Shiyu Liu, 1 Mingjie Xu, 1 Ge Liang, 2 Dan Du, 3 Tingting Liu, 1 Fei Cai, 1 Zhiyao Chen, 1 Qingyuan Tan, 1 Lihui Deng, 1 Qing Xia 1 1 Pancreatitis Centre, Department and Laboratory of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China; 2 Laboratory of Clinical Proteomics and Metabolomics, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, People's Republic of China; 3 Advanced Mass Spectrometry Center, Research Core Facility, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lihui Deng, Pancreatitis Centre, Department and Laboratory of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China, Email Background: Acute pancreatitis (AP) is an inflammatory disorder of the exocrine pancreas without specific treatment. Shenmai injection (SMI) was reported to eliminate the severity of experimental AP. This study aimed to explore the mechanisms underlying the synergistic protective effects of SMI on AP based on network pharmacology and experimental validation. Methods: Network pharmacology analysis and molecular docking based on identified components were performed to construct the potential therapeutic targets and pathways. The principal components of SMI were detected via ultra-high-performance liquid chromatography-coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS). Effect of SMI and the identified components on cellular injury and IL6/STAT3 signaling was assessed on mouse pancreatic acinar cell line 266– 6 cells. Finally, 4% sodium taurocholate (NaT) was used to induce AP model to assess the effects of SMI in treating AP and validate the potential molecular mechanisms. Results: By searching the TCMSP and ETCM databases, 119 candidate components of SMI were obtained. UHPLC-QTOF/MS analysis successfully determined the representative components of SMI: ginsenoside Rb1, ginsenoside Rg1, ginsenoside Re, and ophiopogonin D. Fifteen hub targets and eight related pathways were obtained to establish the main pharmacology network. Subnetwork analysis and molecular docking indicated that the effects of these four main SMI components were mostly related to the interleukin (IL) 6/STAT3 pathway. In vitro, SMI, ginsenoside Rb1, ginsenoside Rg1, ginsenoside Re, and ophiopogonin D increased the cell viability of NaT-stimulated mouse pancreatic acinar 266– 6 cells and decreased IL6 and STAT3 expression. In vivo, 10 mL/kg SMI significantly alleviated the pancreatic histopathological changes and the expression of IL6 and STAT3 in the AP mice. Conclusion: This study demonstrated SMI may exert anti-inflammatory effects against AP by suppressing IL6/STAT3 activation, thus providing a basis for its potential use in clinical practice and further study in treating AP. Keywords: acute pancreatitis, Shenmai injection, network pharmacology, molecular docking, IL6/STAT3 signaling pathway Acute pancreatitis (AP) is one of the most common gastrointestinal diseases, with an estimated cost of approximately 2.6 billion dollars annually and the global incidence is still increasing. 1,2 Intra-acinar events leading to the inflammatory cascade amplify systemic inflammatory response syndrome and ultimately lead to multiple organ dysfunction syndromes and death. Severe AP is characterized by persistent organ failure with a substantial mortality rate of 36–50% and causing the reduced quality of life and significant socioeconomical burden. 3–5 Recent network meta-analysis that included 7366 participants in 78 randomized controlled trials assessing the effects of pharmacological interventions on AP found no consistent clinical benefits from any interventions. 6 Current guidelines recommended routine methods for managing AP. 7,8 Traditional Chinese medicine (TCM) has been clinically applied for thousands of years in China and has been demonstrated to be effective and safe for treating AP in clinical practice. 9 The underlying mechanism of TCM in treating AP remains unclear. Based on TCM theory, AP is triggered by invasion of "heat-evil" to the organs. We proposed the therapeutic principles that require "nourishing Qi and Yin, removing blood stasis, clearing heat, removing toxi -Abstract Truncated-